戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  utility of these fragments in the design of cholesterol-lowering drugs.
2 hway and is inhibited by statins, a class of cholesterol-lowering drugs.
3 effects of rechallenge with statins or other cholesterol-lowering drugs.
4  and cardiac events compared with usual-care cholesterol-lowering drugs.
5                        Statins are effective cholesterol-lowering drugs.
6 rial interventions including another type of cholesterol-lowering drug and (2) inclusion of data on d
7                          For rosuvastatin, a cholesterol-lowering drug and OATP1A/1B substrate, the l
8 disease; and 44% and 50% taking statin-class cholesterol-lowering drugs and aspirin, respectively.
9 nd the development of the newly approved LDL-cholesterol-lowering drugs and critically review their e
10 dwide despite the success of treatments with cholesterol-lowering drugs and drug-eluting stents, rais
11  coronary events in comparison to usual-care cholesterol-lowering drugs and whether perfusion changes
12 iation between statin use (vs. no use of any cholesterol-lowering drug) and the risk of having abnorm
13 cholesterol diet, with or without ezetimibe (cholesterol-lowering drug), and high-fat/high-cholestero
14 between high circulating cholesterol levels, cholesterol-lowering drugs, and breast cancer are confli
15 etitively, reduce LDL levels more than other cholesterol-lowering drugs, and lower triglyceride level
16  of renal patients of interventions (such as cholesterol-lowering drugs, antihypertensives, aspirin,
17 t studies have indicated statins, a class of cholesterol-lowering drugs, as a potential therapy for A
18 ssociated with increased AD risk, and use of cholesterol-lowering drugs associated with decreased ris
19 e KRAS(G12D)-induced LCH-like mouse with the cholesterol-lowering drug atorvastatin ameliorated the p
20 lytic process involved in the synthesis of a cholesterol-lowering drug, atorvastatin (Lipitor), and w
21  (HMG-CoA) reductase inhibitors are powerful cholesterol-lowering drugs, but their broad use in trans
22   An important example of such drugs are the cholesterol-lowering drugs called 'statins', including Z
23                                     Statins, cholesterol-lowering drugs, can delay metastasis formati
24 revious discoveries that statins, a class of cholesterol-lowering drugs, can enhance the cell surface
25 eral decades are needed to determine whether cholesterol-lowering drugs cause cancer in humans.
26 tin, a Food and Drug Administration-approved cholesterol-lowering drug, could protect against nigrost
27 lutaryl-CoA reductase inhibitors, a class of cholesterol-lowering drugs, could interrupt Ang II signa
28 n of Atorvastatin (AT) versus the non-statin cholesterol-lowering drug, Ezetimibe (EZT) on severity o
29 holesterol homeostasis and its response to a cholesterol-lowering drug, ezetimibe.
30          The medications were pravastatin, a cholesterol-lowering drug for the prevention of cardiova
31                               Current use of cholesterol-lowering drugs for five or more years was no
32                     Statins were designed as cholesterol-lowering drugs for the prevention of coronar
33  metabolites in fungi, such as lovastatin, a cholesterol-lowering drug from Aspergillus terreus.
34 lved epidemiological observation that use of cholesterol-lowering drugs has no effect on breast cance
35                                Lovastatin, a cholesterol-lowering drug, has antiproliferative propert
36 ously been shown that atorvastatin (Ator), a cholesterol-lowering drug, has some reducing effect on t
37 itors, which are the most commonly used oral cholesterol-lowering drugs, have immunomodulatory proper
38 d not forget that niacin is an effective LDL-cholesterol-lowering drug in patients with high LDL leve
39 e-lowering drugs, glucose-lowering drugs, or cholesterol-lowering drugs in adults with cardiovascular
40  antihyperglycaemic drugs and non-statin LDL-cholesterol-lowering drugs in patients with type 2 diabe
41                                     Statins, cholesterol-lowering drugs, inhibit these deleterious pr
42  to oral hypoglycemic, antihypertensive, and cholesterol-lowering drugs into its Medicare Advantage q
43  of nonsteroidal anti-inflammatory drugs and cholesterol-lowering drugs is consistent with a macropha
44 bility to inhibit bunyaviruses with existing cholesterol-lowering drugs may offer new options for fut
45 tal structures of hCE1 in complexes with the cholesterol-lowering drug mevastatin, the breast cancer
46 e relative risk for current users of general cholesterol-lowering drugs, mostly statins in this cohor
47 later in life and maternal intervention with cholesterol-lowering drugs or antioxidants reduce postna
48       Here, I propose that rather than being cholesterol-lowering drugs per se, statins act as vitami
49 ned the association between long-term use of cholesterol-lowering drugs, predominantly statins, and t
50                   Notably, administering the cholesterol-lowering drug probucol normalized FC levels
51 tivating the apoAI gene or administering the cholesterol-lowering drug probucol.
52  trials of cardiovascular outcomes of an LDL cholesterol-lowering drug recommended by the 2018 Americ
53 late caveolin/caveolae expression, including cholesterol-lowering drugs, reversed the increased CCE a
54 ost hoc analyses of randomized trials of LDL cholesterol-lowering drugs showed a causal link between
55                                          The cholesterol-lowering drug simvastatin has been shown to
56                                          The cholesterol-lowering drug simvastatin promotes bone form
57 n of hPXR both alone and in complex with the cholesterol-lowering drug SR12813 at resolutions of 2.5
58 ns with the 231 patients who did not use any cholesterol-lowering drugs, statin use was associated wi
59                        Here we show that the cholesterol-lowering drugs statins decrease castration-i
60                              The widely used cholesterol-lowering drugs, statins, were reported to re
61  the common chiral side chain of statin-type cholesterol-lowering drugs such as Lipitor (atorvastatin
62 s that could cause adverse drug reactions to cholesterol-lowering drugs such as statins.
63              Similarly, pravastatin, another cholesterol-lowering drug, suppressed microglial inflamm
64                                  Statins are cholesterol-lowering drugs, targeting HMG-CoA reductase,
65                                Lovastatin, a cholesterol-lowering drug, temporally elevates cell-surf
66  treatment of macrophages with lovastatin, a cholesterol-lowering drug that blocks farnesylation and
67 when the mice were treated with Ezetimibe, a cholesterol-lowering drug that blocks intestinal dietary
68                Statins are widely prescribed cholesterol-lowering drugs that are a first-line treatme
69                Statins are well-established, cholesterol-lowering drugs that can reduce inflammation
70                                  Statins are cholesterol-lowering drugs that have been proven in rand
71 e A (HMG-CoA) reductase enzyme (statins) are cholesterol-lowering drugs that have shown promise as th
72                                  Statins are cholesterol-lowering drugs that inhibit 3-hydroxy-3-meth
73            Statins, a family of FDA-approved cholesterol-lowering drugs that inhibit the rate-limitin
74                        Statins are effective cholesterol-lowering drugs that reduce the risk of cardi
75                      Statins are widely used cholesterol-lowering drugs that selectively inhibit the
76 le, was considered as a potential target for cholesterol-lowering drugs (the role that is now played
77  a decade after the approval of the last LDL-cholesterol-lowering drug, the cholesterol absorption in
78 cal pathway has given rise to a new class of cholesterol-lowering drugs, the proprotein convertase su
79 ls using non-physiological high fat diets or cholesterol-lowering drugs to modify plasma cholesterol,
80 s statins, account for the great majority of cholesterol-lowering drug use.
81 acy of statins, the most prescribed class of cholesterol-lowering drugs used for the prevention and t
82            Lovastatin, a clinically approved cholesterol-lowering drug, was used to modulate caveolae
83                   In the analysis of general cholesterol-lowering drugs, we ascertained 3420 cases of
84                             Simvastatin is a cholesterol-lowering drug whose pleiotropic effects may
85 ed in part on the assumption that overuse of cholesterol-lowering drugs will otherwise become a probl